Applied Therapeutics, Inc. (APLT)

NASDAQ: APLT · IEX Real-Time Price · USD
6.80
-0.05 (-0.73%)
At close: Mar 28, 2024, 4:00 PM
5.80
-1.00 (-14.71%)
After-hours: Mar 28, 2024, 7:57 PM EDT

Company Description

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States.

The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.

It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy.

The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007.

Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Applied Therapeutics, Inc.
Applied Therapeutics logo
Country United States
Founded 2016
IPO Date May 14, 2019
Industry Biotechnology
Sector Healthcare
Employees 25
CEO Dr. Shoshana Shendelman Ph.D.

Contact Details

Address:
545 Fifth Avenue, Suite 1400
New York, New York 10017
United States
Phone 212-220-9226
Website appliedtherapeutics.com

Stock Details

Ticker Symbol APLT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $10.00
CIK Code 0001697532
CUSIP Number 03828A101
ISIN Number US03828A1016
SIC Code 2834

Key Executives

Name Position
Dr. Shoshana Shendelman Ph.D. Chair of the Board of Directors, Founder, President, Chief Executive Officer and Secretary
Les D. Funtleyder Chief Financial Officer, Principal Financial Officer and Independent Director
Dr. Riccardo Perfetti M.D., Ph.D. Chief Medical Officer
Adam Hansard Chief Commercial Officer
Constantine Chinoporos Chief Operating Officer and Chief Business Officer
Catherine Thorpe Chief Accounting Officer

Latest SEC Filings

Date Type Title
Mar 22, 2024 S-3 Registration statement under Securities Act of 1933
Mar 13, 2024 D Notice of Exempt Offering of Securities
Mar 11, 2024 8-K Current Report
Mar 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Mar 6, 2024 10-K Annual Report
Mar 6, 2024 8-K Current Report
Mar 5, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Feb 29, 2024 8-K Current Report
Feb 22, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 15, 2024 8-K Current Report